SUMMARY The absorption of synthetic pteroyltriglutamate has been measured in nine normal students with and without the anticonvulsant drug phenytoin. It has been shown that phenytoin has no effect on the absorption of this folate polyglutamate. The reasons are discussed for the disparity between this result and those reported in the literature when folate polyglutamates derived from yeast were used.
Patients on anticonvulsant therapy may develop megaloblastic anaemia due to folic acid deficiency (Badenoch, 1954; Hawkins and Meynell, 1958) . It has been suggested that folate deficiency is due to interference with the intestinal absorption of folate by the anticonvulsant drugs (Meynell, 1966; Dahlke and Mertens-Roesler, 1967) . Eighty per cent of the folates in the diet are in the form of folate polyglutamates (Butterworth, Santini, and Frommeyer, 1963) which are deconjugated by intestinal enzymes during absorption (Rosenberg and Streiff, 1967) . Hoffbrand and Necheles (1968) and Rosenberg, Godwin, Streiff, and Castle (1968) A fasting blood sample was obtained at 9.00 am, the student then drank 300 ml of water containing 320 ,ug of pteroyltriglutamate. At one of the two absorption tests each subject was also fed a suspension of 200 mg of phenytoin in 25 ml of water three minutes before drinking the folate solution.
Whether the phenytoin was taken at the first or second absorption test was decided randomly. Blood samples were then obtained by venipuncture at one, two, and three hours after the oral dose. The 'peak rise' in the serum folate level was determined by subtracting the fasting value from the highest serum folate level obtained after the oral pteroyltriglutamate.
The triglutamate form of folic acid (pteroyltriglutamate) was prepared by the method of Krumdieck and Baugh (1969) . Thin-layer and paper chromatography showed it to be in excess of 95% pure. There was no detectable contamination with pteroyl-di or mono-glutamate. In addition microbiological assay with Streptococcus faecalis (ATCC 8043) showed the preparation to be free of pteroylmonoglutamate. The oral dose of pteroyltriglutamate was measured by an extinction coefficient (320 ,ug pteroyltriglutamate is equivalent to 200 ,gg of free folic acid).
The serum folates were assayed by the method of Davis, Nicol, and Kelly (1970) (1968) showed that phenytoin inhibited the absorption of partially purified folate polyglutamate derived from yeast. In our study the dose of phenytoin used was twice that used by the above authors but no effect could be demonstrated on a synthetic 95 % pure folate triglutamate.
In both of the former studies the subjects on whom the folate tolerance tests were performed were not preloaded with folic acid to saturate their tissue stores. Clarke (1953) and Chanarin, Anderson, and Mollin (1968) have shown that it is essential to give a loading dose of folic acid in order to saturate the tissues before the tolerance test if uniform serum levels are to be obtained.
This discrepancy in techniques may explain the differences in the results of this study as compared with those of Hoffbrand and Necheles (1968) and Rosenberg et al (1968) . These authors also demonstrated that the deconjugase activity of small intestinal biopsies can be suppressed in vitro; however, even at concentrations of phenytoin in excess of those likely to occur in vivo, deconjugase activities of at least 25% of the original levels were still recovered. The present study would suggest that the deconjugase activity, even if it is partially suppressed in vivo by phenytoin, is not impaired to the extent of altering the rate of folate polyglutamate absorption at a physiological dose level.
Another possibility, albeit unlikely, which could explain the discrepancy in the reported results, is that yeast polyglutamate contains an inhibitor of folate absorption (Swendseid, Bird, Brown, and Bethell, 1947) and that this is potentiated by phenytoin. 
